Comparative analyses suggest that mesothelin outperforms fibulin-3 as a diagnostic marker in pleural effusions and plasma, while fibulin-3 may hold greater prognostic value.18,19 Evidence indicates that fibulin-3 promotes malignant behaviour in mesothelial cells, with knockdown studies showing reductions in cell viability, clonogenicity, invasiveness, and chemoresistance.20 The gene discussed is MSLN; the disease is Pleural effusion.